

H¹
rel. comprises (a) amino acids 79-189 of Figure 7 and (b) a sufficient number of consecutive amino acids 32-78 of Figure 7 to confer on said polypeptide epithelial cell specificity.

H² 49. (Twice Amended) A method of accelerating or improving the healing of a wound involving tissue of epithelial origin, said method comprising administering to the wound site of a patient, an epithelial cell stimulating amount of a glycosylated or unglycosylated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises (a) amino acids 79-189 of Figure 7 and (b) a sufficient number of consecutive amino acids 32-78 of Figure 7 to confer on said polypeptide epithelial cell specificity.

H³ 57. (Twice Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a glycosylated or unglycosylated keratinocyte growth factor (KGF) polypeptide comprising the amino acid sequence of Figure 7, or a segment of said sequence, wherein said segment comprises a sufficient number of consecutive amino acids 32-78 of Figure 7 to confer on said polypeptide epithelial cell specificity.

H⁴ 73. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a glycosylated or unglycosylated keratinocyte growth factor (KGF) polypeptide comprising amino acids 32-194 of Figure 7.

H⁵ 82. (Twice Amended) A method of stimulating epithelial cells in wound tissue, the method comprising administering to said wound tissue an epithelial cell stimulating amount of a glycosylated or unglycosylated keratinocyte growth factor (KGF) polypeptide comprising the amino acid sequence of Figure 7 or a segment of said sequence, wherein said segment comprises a sufficient number of consecutive amino acids 32-78 of Figure 7 to confer on said polypeptide epithelial cell specificity.

N6 114. (Twice Amended) A method of stimulating epithelial cells *in vitro* comprising contacting epithelial cells with an epithelial cell stimulating amount of a glycosylated or unglycosylated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises (a) amino acids 79-189 of Figure 7 and (b) a sufficient number of consecutive amino acids 32-78 of Figure 7 to confer on said polypeptide epithelial cell specificity.

N7 121. (Twice Amended) A method of treating an epithelial skin condition caused by over-expression of Keratinocyte Growth Factor (KGF), comprising topically applying to skin effected by said condition, a therapeutically effective amount of a compound, wherein in an *in vitro* bioassay, said compound inhibits a Keratinocyte Growth Factor (KGF) protein comprising the amino acid sequence of Figure 7 from stimulating epithelial cell mitogenesis, wherein said compound comprises an active ingredient that is selected from the group consisting of an anti-KGF antibody and a fragment of said antibody.

N8 126. (Twice Amended) A method of treating a patient having an epithelial skin condition caused by over-expression of Keratinocyte Growth Factor (KGF) comprising administering to said patient a therapeutically effective amount of a compound, wherein in an *in vitro* assay, said compound inhibits a Keratinocyte Growth Factor protein comprising the amino acid sequence of Figure 7 from stimulating epithelial cell mitogenesis, wherein said compound comprises an active ingredient that is selected from the group consisting of an anti-KGF antibody and a fragment of said antibody.

N9 129. (Twice Amended) A method of inhibiting a Keratinocyte Growth Factor from stimulating epithelial cells in an *in vitro* medium comprising applying a compound to said medium, wherein in an *in vitro* bioassay, said compound inhibits a Keratinocyte Growth Factor comprising the amino acid sequence of Figure 7 from stimulating epithelial cell mitogenesis wherein said compound comprises an active ingredient that is selected from the group consisting of an antibody and a fragment of an antibody.

N¹⁰ 133. (Amended) The method of claim 38 or claim 147, wherein five nanomolar of said polypeptide elicits less than one-fold stimulation over background in NIH/3T3 cells, as measured by percent of maximal H³-thymidine incorporation.

N¹¹ 135. (Amended) The method of claim 49 or 138, wherein five nanomolar of said polypeptide elicits less than one-fold stimulation over background in NIH/3T3 cells, as measured by percent of maximal H³-thymidine incorporation.

N¹² 137. (Amended) The method of claim 57, wherein five nanomolar of said polypeptide elicits less than one-fold stimulation over background in NIH/3T3 cells, as measured by percent of maximal H³-thymidine incorporation.

N¹³ 139. (Amended) The method of claim 82, wherein five nanomolar of said polypeptide elicits less than one-fold stimulation over background in NIH/3T3 cells, as measured by percent of maximal H³-thymidine incorporation.

N¹⁴ 141. (Amended) The method of claim 114 or 149, wherein five nanomolar of said polypeptide elicits less than one-fold stimulation over background in NIH/3T3 cells, as measured by percent of maximal H³-thymidine incorporation.

Please add the following new claims:

142. A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a glycosylated or unglycosylated Keratinocyte Growth Factor (KGF) polypeptide comprising the amino acid sequence of Figure 7, or a segment of said sequence, wherein said polypeptide has mitogenic activity on BALB/MK keratinocyte cells.

143. The method of claim 142, wherein an amount of said polypeptide that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than one-fold stimulation over background in NIH/3T3 fibroblasts.

NS 144. The method of claim 142, wherein an amount of said polypeptide that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than $1/50^{\text{th}}$ of the maximal thymidine incorporation in NIH/3T3 cells stimulated by aFGF or bFGF.

145. The method of claim 142, wherein an amount of said polypeptide that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than $1/10^{\text{th}}$ of the maximal thymidine incorporation in NIH/3T3 fibroblasts stimulated by EGF or TGF-alpha.

146. The method of claim 142, wherein the maximal thymidine incorporation in BALB/MK keratinocytes stimulated by said polypeptide obtained within the concentration range of 0.1 to 3 nanomolar is at least twice that obtained with bFGF within the same concentration range.

147. A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a glycosylated or unglycosylated

keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises (a) amino acids 65-189 of Figure 7 and (b) a sufficient number of consecutive amino acids 32 -64 of Figure 7 to confer on said polypeptide epithelial cell specificity.

148. A method of accelerating or improving the healing of a wound involving tissue of epithelial origin, said method comprising administering to the wound site of a patient, an epithelial cell stimulating amount of a glycosylated or unglycosylated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises (a) amino acids 65-189 of Figure 7 and (b) a sufficient number of consecutive amino acids 32 -64 of Figure 7 to confer on said polypeptide epithelial cell specificity.

HIS
correl.

149. A method of stimulating epithelial cells *in vitro* comprising contacting epithelial cells with an epithelial cell stimulating amount of a glycosylated or unglycosylated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises (a) amino acids 65-189 of Figure 7 and (b) a sufficient number of consecutive amino acids 32 -64 of Figure 7 to confer on said polypeptide epithelial cell specificity.

REMARKS

This, applicants' second filing under Rule 129, is proper because this application claims the benefit of priority from an application that was pending for more than two years as of June 8, 1995, the claims are finally rejected but no Brief on Appeal has been filed and this case is not abandoned. The Examiner did not enter the amendment filed September 15, 2000. Thus, claims 38-121, 123-126, 128, 129 and 131-141 are pending in this case. Applicants herewith cancel claims 46, 47, 48, 56, and 120, without prejudice or disclaimer and add new claims 142-149. Thus, with the entry of this amendment, claims 38-45, 49-55, 57-119, 121, 123-126, 128, 129 and 131-149 will be active in this case.